Grifols SA announced on June 11, 2025, that its subsidiary accepted 416,922 ordinary shares and 3,002,804 non-voting preferred shares of Biotest, totaling €108,011,766 for the Delisting Offer, with 99.25% of voting shares and 61.40% of non-voting shares to be owned after settlement on June 16, 2025.